AKT1 and prostate cancer: Moreover, the association between the activity of the Akt/mTOR pathway and metastatic progression has been reported in various cancer types, including colorectal cancer [29], hepatocellular carcinoma [30], endometrial cancer [31], ovarian cancer [32], gastric cancer [33], melanoma [34], glioma [35], pancreatic ductal adenocarcinoma [36], nasopharyngeal carcinoma [37], osteosarcoma [38], breast cancer [39] and prostate cancer [40].